Interestingly, a recent in vitro study reported that the FGFR inhibitor infigratnib was able to inhibit FGF10/FGFR2 signalling in CCA cell lines, resulting in suppression of cell migration35. Here, FGFR2 is linked to cholangiocarcinoma.